1,202 Shares in argenx SE (NASDAQ:ARGX) Purchased by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB acquired a new position in argenx SE (NASDAQ:ARGX) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 1,202 shares of the company’s stock, valued at approximately $652,000.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the period. Fiera Capital Corp grew its position in argenx by 2.2% in the 2nd quarter. Fiera Capital Corp now owns 165,595 shares of the company’s stock valued at $71,212,000 after acquiring an additional 3,506 shares during the last quarter. Simplify Asset Management Inc. increased its stake in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after purchasing an additional 944 shares during the period. Perpetual Ltd bought a new stake in shares of argenx during the third quarter worth $76,314,000. Finally, Varma Mutual Pension Insurance Co boosted its stake in shares of argenx by 20.0% during the second quarter. Varma Mutual Pension Insurance Co now owns 6,000 shares of the company’s stock valued at $2,580,000 after purchasing an additional 1,000 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

argenx stock opened at $607.21 on Monday. argenx SE has a 1-year low of $327.73 and a 1-year high of $630.00. The business has a fifty day moving average price of $581.03 and a 200-day moving average price of $515.48. The stock has a market capitalization of $36.66 billion, a price-to-earnings ratio of -690.01 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter last year, the company earned ($1.25) earnings per share. On average, equities research analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ARGX shares. Evercore ISI raised their price target on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $617.00 price objective on shares of argenx in a research note on Wednesday, November 20th. JPMorgan Chase & Co. raised their price objective on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Finally, Truist Financial upped their target price on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $635.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.